Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Nontoxic Goiter Medication

  • Author: Stephanie L Lee, MD, PhD; Chief Editor: George T Griffing, MD  more...
 
Updated: Feb 04, 2013
 

Medication Summary

No specific treatment for nontoxic goiter exists. Childhood or adult goiter that is established because of iodine deficiency does not shrink after supplementation with iodine. Goiters due to a defect in thyroid hormone synthesis, dyshormonogenesis, are often reduced in size by thyroid hormone therapy in children. T4 is less effective in shrinking dyshormonogenesis goiter in adults once hyperplastic nodules have developed. Attempting to shrink sporadic or nontoxic goiters with T4 used to be standard practice, but this therapy has fallen out of favor because of the risks of hyperthyroidism, with its detrimental effects on bone and cardiac function, and lack of efficacy to shrink thyroid nodules and goiters.

Next

Thyroid hormones (L-thyroxine)

Class Summary

T4 has been used to reduce the size or suppress the further growth of goiters.

Levothyroxine (Synthroid, Levoxyl, Unithroid, Levothroid)

 

Minimal excess doses of T4 suppress thyrotropin (TSH) secretion from the pituitary. TSH is the primary stimulator of thyroid gland growth and thyroid hormone synthesis. For many years, the standard therapy of nontoxic goiter has been suppression of thyroid function by exogenous T4 therapy. This practice has been largely abandoned because of data showing cortical bone loss with chronic excess of thyroid hormone therapy and lack of benefit in suppressing growth of large nodular goiters. Studies have shown that T4 therapy is most effective in decreasing the size of small diffuse goiters in patients with a basal TSH within the reference range.

Previous
Next

Antithyroid agents

Class Summary

Reduce goiter size.

Sodium iodide, or131 I (Iodotope)

 

Ultrasonographic studies have shown a decrease in thyroid volume after131 I therapy in the majority of patients with nontoxic goiter. When administered at a dose of 100 µCi per g of goiter (corrected for percent uptake of131 I at 24 h), thyroid volume decreases an average of 50-60% in 12-18 mo. In most patients, radioactive iodine therapy reduces compressive symptoms. Commonly used in Europe and Latin America but is not standard therapy in the United States unless the patient has contraindication for surgery. Theoretical concerns of radiation-induced swelling and worsening of compressive symptoms have not been supported in European studies. Often, low-iodine diets are recommended for 5 d up to several wk before therapy.

Previous
 
 
Contributor Information and Disclosures
Author

Stephanie L Lee, MD, PhD Associate Professor, Department of Medicine, Boston University School of Medicine; Director of Thyroid Health Center, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Fellow, Association of Clinical Endocrinology

Stephanie L Lee, MD, PhD is a member of the following medical societies: American College of Endocrinology, American Thyroid Association, Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Sonia Ananthakrishnan, MD Assistant Professor of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Boston University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kent Wehmeier, MD Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine

Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Steven R Gambert, MD Professor of Medicine, Johns Hopkins University School of Medicine; Director of Geriatric Medicine, University of Maryland Medical Center and R Adams Cowley Shock Trauma Center

Steven R Gambert, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American College of Physicians, American Geriatrics Society, Endocrine Society, Gerontological Society of America, Association of Professors of Medicine

Disclosure: Nothing to disclose.

References
  1. Bahn RS, Castro MR. Approach to the patient with nontoxic multinodular goiter. J Clin Endocrinol Metab. 2011 May. 96(5):1202-12. [Medline].

  2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov. 19(11):1167-214. [Medline].

  3. Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab. 2008 Dec. 22(6):929-39. [Medline].

  4. Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008 Jul. 32(7):1313-24. [Medline].

  5. Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf). 2007 Jun. 66(6):757-64. [Medline].

  6. Baczyk M, Pisarek M, Czepczynski R, Ziemnicka K, Gryczynska M, Pietz L, et al. Therapy of large multinodular goitre using repeated doses of radioiodine. Nucl Med Commun. 2009 Mar. 30(3):226-31. [Medline].

  7. Bonnema SJ, Hegedus L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes. 2009 Oct. 16(5):379-84. [Medline].

  8. Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid. 2008 May. 18(5):509-16. [Medline].

  9. Medeiros-Neto G, Marui S, Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine. 2008 Apr. 33(2):109-17. [Medline].

  10. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008 Oct. 14(7):832-9. [Medline].

  11. Fast S, Nielsen VE, Grupe P, et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009 May. 50(5):732-7. [Medline].

  12. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun. 21(6):593-646. [Medline].

  13. Yetkin G, Uludag M, Onceken O, et al. Does unilateral lobectomy suffice to manage unilateral nontoxic goiter?. Endocr Pract. 2010 Jan-Feb. 16(1):36-41. [Medline].

  14. Phitayakorn R, McHenry CR. Follow-up after surgery for benign nodular thyroid disease: evidence-based approach. World J Surg. 2008 Jul. 32(7):1374-84. [Medline].

  15. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Five-year Follow-up of a Randomized Clinical Trial of Total Thyroidectomy versus Dunhill Operation versus Bilateral Subtotal Thyroidectomy for Multinodular Nontoxic Goiter. World J Surg. 2010 Feb 20. [Medline].

  16. Worni M, Schudel HH, Seifert E, et al. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg. 2008 Dec. 248(6):1060-6. [Medline].

  17. Erbil Y, Barbaros U, Temel B, et al. The impact of age, vitamin D(3) level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. Am J Surg. 2009 Apr. 197(4):439-46. [Medline].

  18. Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet. 1990 Jul 28. 336(8709):193-7.

  19. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999 Oct. 84(10):3636-41. [Medline]. [Full Text].

  20. Braverman LE, Utiger RD, Hermus AR, Huysmans DA:. Clinical manifestations and treatment of nontoxic diffuse and nodular goiter. In: Werner & Ingbar's The Thyroid. Baltimore, Md: Lippincott Williams & Wilkins;. 2000. 866-871.

  21. Hegedus L, Gerber H. Multinodular goiter. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 2001. 2:1517-1528.

  22. Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med. 1998 May 14. 338(20):1438-47. [Medline].

  23. Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab. 1998 Oct. 83(10):3401-8. [Medline]. [Full Text].

  24. Huysmans D, Hermus A, Edelbroek M, et al. Radioiodine for nontoxic multinodular goiter. Thyroid. 1997 Apr. 7(2):235-9. [Medline].

  25. Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994 Nov 15. 121(10):757-62. [Medline].

  26. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab. 2000 Oct. 85(10):3592-6. [Medline]. [Full Text].

  27. Netterville JL, Coleman SC, Smith JC, et al. Management of substernal goiter. Laryngoscope. 1998 Nov. 108(11 Pt 1):1611-7. [Medline].

  28. Perrild H, Hansen JM, Hegedus L. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh). 1982 Jul. 100(3):382-7. [Medline].

  29. Rios A, Rodriguez JM, Canteras M, et al. Surgical management of multinodular goiter with compression symptoms. Arch Surg. 2005 Jan. 140(1):49-53. [Medline]. [Full Text].

  30. Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid. 1992 Fall. 2(3):263-9. [Medline].

Previous
Next
 
Intrathoracic goiter causing obstruction. This patient has a visible goiter on physical examination. In addition, he has distension of his left external jugular vein, facial erythema (when compared with his shoulder), and cutaneous varicosities of venous blood draining from his head into his chest because of jugular obstruction from his goiter.
Technetium-99m (99mTc) thyroid scan of a large, nontoxic multinodular goiter. Multiple cold and hot nodules are observed in the enlarged thyroid gland. The white arrow indicates sternal notch marker.
Areas of autonomy with excess thyroid hormone secretion in a large nodular goiter. This technetium-99m (99mTc) thyroid scan shows hot and cold nodules in a multinodular goiter. Although the patient's thyroid-stimulating hormone level had become progressively suppressed, it was within the reference range, at 0.4 mU/mL (reference range 0.35-5.5 mU/mL).
Nontoxic goiter of the thyroid gland with tracheal compression. An axial, noncontrast computed tomography scan through the thyroid shows significant tracheal compression.
Relief of tracheal compression after subtotal thyroidectomy of large, obstructive, nontoxic multinodular goiter. (A) Laryngoscopy demonstrating critical tracheal narrowing before thyroidectomy; (B) laryngoscopy showing widened patent trachea after thyroidectomy.
Multinodular goiter. On visual inspection of the neck (image on left), this patient appears to have a goiter. The computed tomography scan (image on right) shows the asymmetrical goiter, measuring 9.3 x 7.4 cm, with tracheal deviation, although no tracheal obstruction is present.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.